Targeting Circadian Rhythm Disruption in Glaucoma: PTGDS Mediates Trabecular Meshwork Fibrosis and Is Therapeutically Targeted by Aprepitant
Translational Vision Science & Technology · 2026
DOI: 10.1167/tvst.15.5.2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Vision Science & Technology, 2026. Verfasst von Hongzhi Yuan und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and …. Hauptthemen laut MEDLINE: Trabecular Meshwork, Glaucoma, Circadian Rhythm, Morpholines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
Trabecular meshwork (TM) fibrosis, which causes ocular hypertension (OHT), remains a key therapeutic challenge in glaucoma. Given the emerging link between circadian rhythm disruption and glaucoma, we sought to identify novel fibrotic mediators related to circadian genes, and screen for potential inhibitors to assess their therapeutic effect.
Methods
We performed an integrated analysis of human TM transcriptome data to identify key circadian rhythm-related differentially expressed genes (CRRDEGs). We confirmed the hub gene's upregulation in an OHT mouse model. We then performed virtual screening and molecular docking to identify a potential inhibitor from existing drugs, which was subsequently tested in vitro for anti-fibrotic efficacy.
Results
PTGDS emerged as the hub gene among 15 CRRDEGs, showing significant overexpression in the TM of OHT mice. Virtual screening indicated that aprepitant as the top candidate inhibitor, showing the lowest binding affinity for PTGDS. Subsequent in vitro tests confirmed that aprepitant partially rescued human TM cell viability from TGFβ-induced fibrotic stress. It also effectively downregulated the expression of both PTGDS and established fibrosis markers.
Conclusions
PTGDS, a key circadian-related gene, is a novel mediator of TM fibrosis. Our findings demonstrate that targeting PTGDS with aprepitant can ameliorate the fibrotic phenotype in vitro. This validates PTGDS as a promising, druggable target for glaucoma therapy. Translational Relevance: This study identifies the PTGDS-mediated fibrotic pathway as a druggable target in glaucoma. Our findings provide a preclinical rationale for evaluating the US Food and Drug Administration (FDA)-approved drug aprepitant as a repurposed therapeutic, offering a new strategy for the development of anti-fibrotic treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocul…
- Department of Ophthalmology, the Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong Province, People's Republic of China.
Zitieren
APA
Yuan, H., Che, Y., Zhang, Y., Cai, Z., Ping, Y. T., Wang, X., & Yang, Y. (2026). Targeting Circadian Rhythm Disruption in Glaucoma: PTGDS Mediates Trabecular Meshwork Fibrosis and Is Therapeutically Targeted by Aprepitant. Translational Vision Science & Technology. https://doi.org/10.1167/tvst.15.5.2
Vancouver
Yuan H, Che Y, Zhang Y, Cai Z, Ping YT, Wang X, et al. Targeting Circadian Rhythm Disruption in Glaucoma: PTGDS Mediates Trabecular Meshwork Fibrosis and Is Therapeutically Targeted by Aprepitant. Translational Vision Science & Technology. 2026. doi:10.1167/tvst.15.5.2
BibTeX
@article{Yuan2026,
author = {Yuan, Hongzhi and Che, Yutong and Zhang, Yuqing and Cai, Ziyi and Ping, Yu-Tzu and Wang, Xiaoran and Yang, Yangfan},
title = {Targeting Circadian Rhythm Disruption in Glaucoma: PTGDS Mediates Trabecular Meshwork Fibrosis and Is Therapeutically Targeted by Aprepitant},
journal = {Translational Vision Science & Technology},
year = {2026},
doi = {10.1167/tvst.15.5.2}
}
EUVIMED